GASTROESOPHAGEAL JUNCTION CANCER

This study is testing whether adding a new two-drug immunotherapy (called QL1706) to standard chemotherapy works better for people with advanced stomach or gastroesophageal junction cancer who haven't had prior treatment. About 32 participants will receive the combination therapy…

This study is testing two different combinations of new drugs for people with stomach or gastroesophageal junction cancer who haven't had treatment yet. Researchers want to see if these drug combinations can shrink tumors effectively and are safe for patients. The trial will meas…

This study is testing a new drug called AZD0901 for people with advanced stomach or gastroesophageal cancer that has spread and stopped responding to initial treatments. It compares AZD0901 to the doctor's choice of standard therapies to see which works better at controlling the …

This early-stage trial is testing a new targeted cancer drug called IKS014 in people with advanced HER2-positive solid tumors, including breast and stomach cancers. The main goals are to find the highest safe dose and see if the drug can shrink tumors. The study will enroll about…

This large, late-stage trial is comparing new drug combinations against the current standard treatment for advanced stomach or gastroesophageal cancer that has a specific marker (HER2-positive). It aims to see if adding newer targeted drugs to chemotherapy can better control the …

This study compares two different stomach cancer surgeries to see which one works better for patients with advanced tumors where the stomach meets the esophagus. Patients will be randomly assigned to receive either a partial stomach removal or a complete stomach removal, then fol…

This early-stage study is testing a new drug called AZD4360 in adults with advanced cancers of the stomach, pancreas, and related areas. The main goals are to find a safe dose and see if the drug shows any signs of helping to control the cancer. The drug is designed to target a s…

This study is testing an experimental drug called AZD0901, both by itself and combined with standard chemotherapy, for people with advanced cancers of the stomach, pancreas, and bile ducts. The main goals are to see if the treatment is safe and if it can shrink tumors. It is for …

This large Phase 3 study is testing whether adding a new antibody drug called HLX22 to standard treatment helps people with advanced HER2-positive stomach or gastroesophageal cancer live longer without their cancer getting worse. About 550 adults with previously untreated, advanc…

This study is testing an experimental drug called AZD0901 for people with advanced stomach or gastroesophageal junction cancer that has spread and expresses a specific protein called CLDN18.2. It is for adults whose cancer has continued to grow after at least one prior treatment.…

This early-stage study is testing a new drug called BL-M07D1 for people with advanced cancers that have a specific marker called HER2. The trial aims to find the safest dose and see if the drug helps control cancer growth in patients who have already tried standard treatments. Re…

This early-stage trial is testing a new drug called CA-4948 in combination with standard chemotherapy and immunotherapy for people with advanced stomach or esophageal cancer that cannot be surgically removed. The study aims to find the safest dose of this combination and see if i…

This is an early-stage study to check the safety and initial activity of an experimental drug called DR-0202. It is for adults with advanced cancers that have spread, returned, or stopped responding to at least two prior treatments. The main goal is to find a safe dose and see ho…